Advertisement

The Indian Journal of Pediatrics

, Volume 80, Issue 7, pp 549–554 | Cite as

Clinical and Echocardiographic Outcome in Patients Receiving Carvedilol for Treatment of Dilated Cardiomyopathy

  • Anita SaxenaEmail author
  • Om Murty Anil
  • Rajnish Juneja
Original Article

Abstract

Objective

To determine outcome of children receiving carvedilol in addition to other standard drug therapy for treatment of dilated cardiomyopathy.

Methods

Children receiving carvedilol for treatment of dilated cardiomyopathy with moderate to severe ventricular dysfunction were included into the study. Data on history, clinical examination and investigations were obtained and detailed echocardiography findings were recorded for the initial and all subsequent visits.

Results

Thirty-three children, mean age 26 ± 30 mo (range 7 mo to 138 mo) were enrolled. Carvedilol was initiated at a mean dose of 0.14 ± 0.03 mg/kg/d and the maintenance dose was 0.46 ± 0.14 mg/kg/d. At a follow up of 6–90 mo (mean of 28 ± 23 mo), functional class using Ross classification for pediatric heart failure improved from 2.7 to 1.3. The left ventricular ejection fraction rose from a basal value of 22 % ± 7 % (10–40 %) to 42 % ± 15 % (15–65 %) (p < 0.0001). Similarly, left ventricular fractional shortening increased significantly from 16 ± 6 % (8–34 %) to 21 ± 7 % (10–44 %) (p < 0.0001). One patient deteriorated and died of refractory heart failure. Carvedilol was discontinued in two more patients temporarily due to bronchospasm during respiratory infection.

Conclusions

The present study suggests that improvement in ventricular function and clinical symptoms is seen on oral carvedilol added to standard drug therapy in pediatric patients with dilated cardiomyopathy and moderate to severe ventricular dysfunction. The drug is well tolerated with minimal side effects but close monitoring is required as it may worsen heart failure and bronchospasm.

Keywords

Dilated cardiomyopathy Carvedilol Heart failure 

Notes

Conflict of Interest

None.

Role of Funding Source

None.

References

  1. 1.
    Rosenthal D, Chrisant MR, Edens E, et al. International society for heart and lung transplantation: practice guidelines for management of heart failure in children. J Heart Lung Transplant. 2004;23:1313–33.PubMedCrossRefGoogle Scholar
  2. 2.
    Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial. Prospective randomized evaluation of carvedilol on symptoms and exercise. Circulation. 1996;94:2793–99.PubMedCrossRefGoogle Scholar
  3. 3.
    Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283:1295–302.PubMedCrossRefGoogle Scholar
  4. 4.
    Eichhorn JE, Bristow MR. The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Curr Control Trials Cardiovasc Med. 2001;2:20–3.PubMedCrossRefGoogle Scholar
  5. 5.
    Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomized controlled trial. Lancet. 2003;362:7–13.PubMedCrossRefGoogle Scholar
  6. 6.
    Bristow MR. Mechanism of action of beta blocking agents in heart failure. Am J Cardiol. 1997;80:26L–40L.PubMedCrossRefGoogle Scholar
  7. 7.
    Shaddy RE, Olsen SL, Bristow MR, et al. Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J. 1995;129:197–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Shaddy RE, Tani LY, Gidding SS, et al. Beta blocker treatment of dilated cardiomyopathywith congestive heart failure in children: a multi-institutional experience. J Heart Lung Transplant. 1999;18:269–74.PubMedCrossRefGoogle Scholar
  9. 9.
    Bruns LA, Chrisant MK, Lamour JM, et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr. 2001;138:505–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Azeka E, Franchini Ramires JA, Valler C, Alcides Bocchi E. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol. 2002;40:2034–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Rusconi P, Gomez-Marin O, Rossique-Gonzalez M, et al. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant. 2004;23:832–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Blume ED, Canter CE, Spicer R, Gauvreau K, Colan S, Jenkins KJ. Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol. 2006;27:336–42.PubMedCrossRefGoogle Scholar
  13. 13.
    Shaddy RE, Boucke MM, Hsu DT, Pediatric Carvedilol Study Group, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA. 2007;298:1171–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Ross RD, Bollinger RO, Pinsky WW. Grading the severity of congestive heart failure in infants. Pediatr Cardiol. 1992;13:72–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Akagi T, Benson LN, Lightfoot NE, Chin K, Wilson G, Freedom RM. Natural history of dilated cardiomyopathy in children. Am Heart J. 1991;121:1502–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Bostan OM, Cil E. Dilated cardiomyopathy in childhood: prognostic features and outcome. Acta Cardiol. 2006;61:169–74.PubMedCrossRefGoogle Scholar
  17. 17.
    Saad IA. Idiopathic dilated cardiomyopathy in children; Natural history and predictors of prognosis. Libyan J Med. 2007;2:129–34.PubMedCrossRefGoogle Scholar
  18. 18.
    Pitt B, Zannad P, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.PubMedCrossRefGoogle Scholar
  19. 19.
    Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS trial study group. N Engl J Med. 1987;316:1429–35.Google Scholar
  20. 20.
    The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.CrossRefGoogle Scholar
  21. 21.
    Saxena A, Juneja R, Ramakrishnan S, Working Group on Management of Congenital Heart Diseases in India. Drug therapy of cardiac diseases in children. Indian Pediatr. 2009;46:310–38.PubMedGoogle Scholar
  22. 22.
    Shaddy RE. Beta-blocker therapy in young children with congestive heart failure under consideration for heart transplantation. Am Heart J. 1998;136:19–21.PubMedCrossRefGoogle Scholar
  23. 23.
    Gachara N, Prabhakaran S, Srinivas S, Farzana F, Krishnan U, Shah MJ. Efficacy and safety of carvedilol in infants with dilated cardiomyopathy: a preliminary report. Indian Heart J. 2001;53:74–8.PubMedGoogle Scholar
  24. 24.
    Laer S, Mir TS, Behn F, et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J. 2002;143:916–22.PubMedCrossRefGoogle Scholar
  25. 25.
    Askari H, Semizel E, Bostan OM, Cil E. Carvedilol therapy in pediatric patients with dilated cardiomyopathy. Turk J Pediatr. 2009;51:22–7.PubMedGoogle Scholar
  26. 26.
    Petko C, Minich LL, Everitt MD, Holubkov R, Shaddy RE, Tani LY. Echocardiographic evaluation of children with systemic ventricular dysfunction treated with carvedilol. Pediatr Cardiol. 2010;31:780–4.PubMedCrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2013

Authors and Affiliations

  1. 1.Department of Pediatric CardiologyAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations